Development and Validation of Spectrophotometric Method For Simultaneous Estimation of Rosuvastatin Calcium and Aspirin In Bulk and Pharmaceutical Dosage Form

Rosuvastatin calcium and Aspirin combination is used in the treatment of Cardio vascular diseases.Rosuvastatin calcium is HMG Co-A reductase inhibitor and Aspirin is Antiplatelet agent. Literature survey revealed one UV Spectrophotometric method for simultaneous estimation of Rosuvastatin calcium and Aspirin in combined dosage form. Therefore simple, sensitive, rapid and precise spectrophotometric method has been developed and validated for simultaneous estimation of Rosuvastatin calcium and Aspirin from bulk and its pharmaceutical dosage form. These drugs were estimated in formulation by Q-absorption method in which wavelengths selected were 257nm as iso-absorptive point and 244nm as λmax of Rosuvastatin calcium. Linearity was observed in the concentration range of 10-50 μg/ml and 40-120 μg/ml for Rosuvastatin calcium and Aspirin respectively. Percentage purity and accuracy were in the limit of 98-102% and precision was less than 2 for both drugs. Limit of Detection for Rosuvastatin calcium & Aspirin was found to be 1.6730μg/ml & 7.4278μg/ml respectively. Limit of Quantitation for Rosuvastatin calcium & Aspirin was found to be 5.0696μg/ml & 22.5083μg/ml respectively. Validation study revealed that the method is simple, rapid, specific, accurate, precise, reproducible, robust and economic and can be used for routine quantitative analysis of Rosuvastatin calcium and Aspirin in pure and combined pharmaceutical dosage form.